Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

MRK

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

MRK

AI Research Report

Powered by Claude

Ready to analyze MRK

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Merck & Co Inc

Merck & Co Inc

Pharmaceuticals·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1941-01-01

Factor Grades

View details →
B+
Overall score: 74/100
B-
Valuation
B-
Growth
A
Profitability
B+
Momentum
A-
Financial Health
NEW YORK STOCK EXCHANGE, INC.After-hours
Merck & Co Inc
Pharmaceuticals
$119.96
$-0.19 (-0.16%)
After-hrs · vs prev close $120.15
Open
$119.03
Prev close
$120.15
Day range
$118.15 – $120.36
52W range
$73.31 – $125.14
Mkt cap
$297.06B
P/E
16.3
EPS
$7.28
Beta
0.29
📅 Earnings in 16d (Apr 30)

Fundamentals

Valuation
Market Cap
$297.06B
P/E (TTM)
16.26S&P avg ~22
P/S (TTM)
4.57S&P avg ~2.8
P/B
4.97S&P avg ~4.5
P/FCF
24.01S&P avg ~26
EPS (TTM)
$7.28
Book/sh
$21.26
Cash/sh
$5.89
Profitability
Gross Margin
78.55%avg ~45%
Operating Margin
32.64%avg ~15%
Net Margin
28.08%avg ~12%
ROE
36.19%avg ~18%
ROA
14.63%avg ~7%
ROI
20.13%
Payout Ratio
44.79%
FCF/sh
—
Growth & Health
Rev Growth YoY
1.31%
Rev Growth 5Y
9.38%
EPS Growth YoY
8.02%
EPS Growth 5Y
21.23%
Current Ratio
—
Quick Ratio
1.30
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.29
52W High
$125.14
52W Low
$73.31
Avg Vol (10D)
8.48M
Avg Vol (3M)
12.17M
Div Yield
2.83%
Div/sh (TTM)
—
Analyst
Buy (35)
Price Performance
5D+0.73%
MTD-0.12%
3M+8.25%
6M+35.30%
YTD+14.15%
1Y+54.93%

Analyst Consensus

Buy
Based on 35 analysts
Period: 2026-04-01
24 Buy (69%)11 Hold (31%)0 Sell (0%)
Rating Distribution
Strong Buy
8
Buy
16
Hold
11
Sell
0
Strong Sell
0
Trend
2026-04
24/11/0
2026-03
24/12/0
2026-02
21/13/0
2026-01
22/12/0
  • Yahoo·6h ago

    MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer

    The FDA grants priority review to Merck and Daiichi's BLA for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer.

  • Yahoo·7h ago

    Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says

    Revolution Medicines (RVMD) has several paths toward additional upside on potential M&A deals and a

  • SeekingAlpha·7h ago

    Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway

    Read the latest analysis on Revolution Medicines (RVMD) stock here.

  • Yahoo·12h ago

    1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

  • Yahoo·13h ago

    Merck transforms itself through dealmaking as clock ticks on top-selling drug

    Merck chief executive Rob Davis has turned the pharmaceutical company into the industry’s most aggressive dealmaking machine. The group has spent...

  • Yahoo·13h ago

    How Merck keeps prices for its blockbuster cancer drug sky high

    Merck built a wall of patents to keep a cancer drug's price – and its profits – high. Hospitals often add to the cost for American patients.

  • Yahoo·1d ago

    Merck (MRK) Stock Sinks As Market Gains: Here's Why

    In the latest trading session, Merck (MRK) closed at $120.15, marking a -1.05% move from the previous day.

  • Yahoo·1d ago

    1 Momentum Stock on Our Buy List and 2 We Question

    Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

  • View all news →
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B5 on 2025-12-03. View all →

Recent insider activity

View all →
  • 4PRIMARY DOCUMENT
    13d ago
  • 4PRIMARY DOCUMENT
    13d ago
  • 4PRIMARY DOCUMENT
    13d ago
  • 4PRIMARY DOCUMENT
    Feb 12
  • 4PRIMARY DOCUMENT
    Feb 10